

Doxorubicin

Essential medicine status

General description

Doxorubicin is an anthracycline antineoplastic agent, used in treatment protocols for various cancers.

INN

Doxorubicin

ATC codes

[L01DB01](#) [L01AA01](#)

Medicine type

Chemical agent

EML status history

First added in 1977 ([TRS 615](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2011 ([TRS 965](#)) for [Lymphoid leukaemia, not elsewhere classified](#)

Added in 2011 ([TRS 965](#)) for [Burkitt lymphoma including Burkitt leukaemia](#)

Added in 2015 ([TRS 994](#)) for [Malignant neoplasms of breast](#)

Added in 2015 ([TRS 994](#)) for [Follicular lymphoma](#)

Added in 2015 ([TRS 994](#)) for [Kaposi sarcoma of unspecified primary site](#)

Added in 2015 ([TRS 994](#)) for [Hodgkin lymphoma](#)

Added in 2015 ([TRS 994](#)) for [Diffuse large B-cell lymphoma, not otherwise specified](#)

Added in 2015 ([TRS 994](#)) for [Malignant neoplasms of kidney, except renal pelvis](#)

Added in 2015 ([TRS 994](#)) for [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)

Added in 2015 ([TRS 994](#)) for [Osteosarcoma of bone and articular cartilage of unspecified sites](#)

Removed in 2015 ([TRS 994](#)) for [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Added in 2015 ([TRS 994](#)) for [Other specified malignant neoplasms of breast](#)

Added in 2019 ([TRS 1021](#)) for [Plasma cell myeloma](#)

Application rejected in 2021 ([TRS 1035](#)) for [Rhabdomyosarcoma primary site](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-positive](#)

Added in 2023 ([TRS 1049](#)) for [Anaplastic large cell lymphoma, ALK-negative](#)

Wikipedia

[Doxorubicin](#)

DrugBank

[Doxorubicin](#)

Recommendations

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)
- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Indications

[Diffuse large B-cell lymphoma, not otherwise specified](#) [Malignant neoplasms of breast](#) [Hodgkin lymphoma](#) [Kaposi sarcoma of unspecified primary site](#) [Follicular lymphoma](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Other specified malignant neoplasms of breast](#) [Plasma cell myeloma](#) [Rhabdomyosarcoma primary site](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Anaplastic large cell lymphoma, ALK-negative](#)